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Special Issue Article
Malaria caused by Plasmodium vivax:
recurrent, difficult to treat, disabling, and
threatening to life — averting the infectious
bite preempts these hazards
J. Kevin Baird1,2
1Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia, 2The Centre for Tropical Medicine, Nuffield
Department of Medicine, University of Oxford, UK
The maxim ‘an ounce of prevention is worth a pound of cure’ finds few better demonstrations than with
malaria caused by Plasmodium vivax. Thoroughly neglected over the past 60 years, the chemotherapy of
this complex infection has been dangerous and ineffective until the present. Work is at last being done, but
seeing that translate to real improvements at the periphery of care delivery will take years of deliberate
effort. In the meantime, patients face substantial risk of debilitating, threatening, and fatal courses of illness
associated with a diagnosis of vivax malaria. For some of the most vulnerable to such outcomes —
pregnant women and infants — repeated attacks of acute vivax malaria from a single infectious anopheline
bite is now not preventable. One of the few measures than can be immediately applied with rigor is vector
control, thereby effectively preventing as many of these difficult and dangerous infections as possible. This
commentary emphasizes the dire consequences of infection by P. vivax and the real difficulty of dealing
with them. That, in turn, emphasizes the many benefits to be derived by preventing them in the first place.
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Onerous Burden
Plasmodium vivax occurs all across the globe, from
the Korean Peninsula to the northern fringes of
Argentina (Fig. 11). The exact number of annual
clinical attacks has not been reliably estimated, but it
is thought to be more than 100 and less than 400
million.2 That number, whatever it really happens to
be, is likely of the same order of magnitude (low
hundred millions) as the estimated number of clinical
attacks of falciparum malaria, i.e. 247 million
according to the World Health Organization,3 or
451 million in according to Hay and colleagues.4
Nonetheless, malariologists have historically dis-
missed the heavy burdens of P. vivax in Asia and
the Americas in weighing the global malaria problem
— largely by supposing the relative harmlessness of
vivax malaria. Most have thus considered the global
malaria problem to be heavily weighted upon a single
continent by a single species (Plasmodium falciparum;
Africa). However, the supposition of harmlessness in
vivax malaria does stand to available evidence5 and
the infection must be combatted with much more
rigor than has been applied in the past.
Biological Complexity
The life cycles of all of the five species of Plasmodium
naturally infecting humans are complex, but P. vivax
(and P. ovale) has a single additional stage that
hugely magnifies its epidemiological and clinical
complexity. This parasite places dormant forms in
the liver that cause multiple clinical attacks (called
relapses) over about 2 years. In contrast, a single
infectious bite with P. falciparum causes a single
attack within less than 2 weeks. The risk, timing, and
frequency of these clinical attacks emanating from
the liver appears evolved to coincide with both a
relatively high likelihood of encountering a different
strain of P. vivax in the blood6 and of the presence of
feeding anopheline mosquitoes in the environment (in
which sexual recombination with that other strain
may occur).
The Chesson and North Korea strains of P. vivax
represent the two extremes of relapse behaviors.
Chesson strain came from an American soldier
infected in New Guinea during the Pacific War.7
Perpetually tropical and rainy New Guinea has a
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virtually uninterrupted abundance of anophelines,
and Chesson strain relapses very often (virtually
100%), very quickly (within 3 weeks of the primary
parasitemia becoming patent), and multiple times
(5 is typical, 15 is known) within 2 years (exception-
ally 3 years). North Korea on the other hand, has a
fleeting summer period where anopheline mosquitoes
will occur, and North Korean P. vivax strain exhibits
no primary parasitemia, but will relapse only 8–
12 months after inoculation.8
Shute and colleagues8 discovered that populations of
sporozoites of North Korean P. vivax consisted of two
types — those that immediately went into full develop-
ment of liver and blood stages, and those that became the
dormant forms responsible for relapse — called hypno-
zoites. The latter greatly outnumbered the former in that
temperate strain, demonstrated by primary parasitemias
after inoculating relatively vast numbers of sporozoites.
This ratio presumably represents adaptation to the
brevity of seasonal anopheline abundance. The parasites
emerge into the relative danger of the bloodstream only
when the likelihood of encountering feeding anophelines
is relatively high. Each such sortie provokes the human
misery known as malaria.
Force of Infection
The hypnozoite impels departure from convention
when considering terminology as basic as ‘infection’.
The biology of falciparum malaria permits classifying
an infectious bite seeding the liver with sporozoites,
and subsequent seeding of the blood by merozoites as
a single infectious event, i.e. an ‘infection’. If one
thinks of the defining event of malaria as the presence
of the disease-causing asexual stages in the blood,
then the term in vivax malaria takes on different
meaning. While hosts harboring quiescent hypno-
zoites are indeed ‘infected’, there is no active blood
infection and therefore, no acute malaria. In this
sense, both mosquitoes and hypnozoites in the liver
may be considered contributors to the force of
infection of the blood.
The liver reservoir of P. vivax in any given endemic
community may indeed be substantial. While it is
now not possible to diagnose latent liver stages, one
can, under some circumstances, observe their force of
infection. One such study reported by Douglas and
colleagues9 reported that among hundreds of patients
diagnosed with acute falciparum malaria in western
Thailand and treated with a rapidly eliminated therapy
(rather than one that lingers in the blood for weeks,
suppressing new parasitemias from any source), 51%
suffered a relapse of P. vivax after just 2 months. That
number may be considered an absolutely minimal
estimation of the prevalence of hypnozoites among
people having falciparum malaria (longer follow-up
would almost certainly have increased that number).
Another study reveals the force of infection by
hypnozoites: Downs et al.10 described malaria attack
rates in the US Army Americal Division engaged in
combat on Guadalcanal in the Solomon Islands of
1942 and 1943. While on that malarious island, the
attack rate was about 1 infection/person-year, despite
chemophrophyaxis (using atebrin, a chloroquine-like
drug). After several months of heavy combat, the
division was evacuated (with mass treatment against
blood but not liver stages of malaria) for rest and
recuperation at Fiji, where no anopheline mosquitoes
occur and malaria transmission is not possible. The
malaria attack rates soared to 4 infections/person-year
on Fiji — almost certainly all representing activation
of hypnozoites.
In some communities, the hypnozoite probably
represents the more common origin of a new blood
infection event. No study has yet measured both
compartments of infection simultaneously. Several
studies in Indonesian Papua, where malaria is very
heavily endemic, consistently showed incidence density
of new infection among subjects (cleared of blood and
liver stage parasites for P. vivax) at about 2 infections/
person-year.11 This was considered to be the force
of infection from mosquitoes, i.e. sporozoite-borne
Figure 1 Global distribution of endemic Plasmodium vivax (from Ref. 1, published under Creative Commons License).
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primary attacks. If each such inoculation then yielded
a modest five infections of blood by activation of
hypnozoites, its force of infection would of course
greatly exceed that number for sporozoites. Such may
not be universally true and will depend upon relapse
behaviors of local strains.
A Threatening Event
Although infection by P. vivax has long been known as
‘benign tertian malaria’, that dogma of harmlessness
has been revealed as fallacious.2,5 Among patients
hospitalized with a primary diagnosis of vivax malaria,
about 10–20% will be classified as having severe illness,
and 5%–15% of those will not survive. These
frequencies approximate those with a diagnosis of
malaria caused by P. falciparum. The syndromes of
severe illness are also broadly similar. Lança et al.12
found that the WHO criteria for severe falciparum
malaria (statistically linked to high risk of a fatal
outcome13) correlated very well with risk of admission
to intensive care units in Brazil with a diagnosis of P.
vivax malaria. The lone exception was count of
parasitemia considered threatening: .250 000/ml for
P. falciparum, whereas in hospitals in Brazil, patients
with P. vivax parasitemia .500/ml were often referred
to intensive care units. Thus, despite seemingly non-
threatening levels of parasitemia in vivax malaria,
patients become seriously and sometimes fatally ill.
Difficult to Treat
Treatment of acute vivax malaria requires two
distinct classes of drugs — blood schizontocide(s)
(to terminate the acute attack), and hypnozoitocide(s)
(to prevent subsequent acute attacks). The two classes
compose what is referred to in malariology as ‘radical
cure’. This partnership comes with a list of ther-
apeutic issues regarding drug–drug interactions
impacting safety or efficacy. Since chloroquine and
primaquine were partnered in this capacity in 1952,
no other pairs of drugs for radical cure of vivax have
been demonstrated safe and effective (excepting
quinine and primaquine, also validated during the
work with chloroquine). Resistance to chloroquine
by P. vivax has been emerging at least since 1990 and
worsens and spreads from its epicenter in eastern
Indonesia.14 Though there are many new blood
schizontocides with good efficacy against chloro-
quine-resistant P. vivax,15 only one has been demon-
strated to come with good safety and efficacy against
relapse when partnered with primaquine (albeit with
dosing delayed by 25 days after treating the acute
attack due to safety concerns).16 The difficulty of
such evaluations will certainly limit therapeutic
options for radical cure of vivax malaria with new
blood schizontocides.
Figure 2 illustrates the principle difficulties in
delivering effective therapy for vivax malaria. The
Figure 2 Diagram illustrating the step-wise loss of primaquine effectiveness in endemic settings.
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only drug effective against relapse of P. vivax is
primaquine, a seriously flawed drug that causes mild
to severe and fatal acute hemolytic anemia in patients
having an inborn deficiency of glucose-6-phosphate
dehydrogenase (G6PD).17 This very complex disorder
affects 400 million people globally, with an average
prevalence in malaria endemic zones of 8%.18 Current
technologies do not permit access to a diagnosis of
G6PD deficiency where most patients live. As a
consequence of fear of causing harm, most providers
either do not prescribe the treatment at all or fail to
implore their patients to take the medication as
directed. The 14 days of daily dosing with primaquine
was designed with G6PD deficiency safety in mind, i.e.
patients taking the drug under recommended clinical
supervision could cease the regimen with onset of signs
of hemolytic reaction. Not providing such supervision
— by sending a patient home with stern instructions to
complete the regimen — invites the danger of the
patient ignoring or not noticing signs of hemolysis and
steadfastly adhering to the doctor’s emphatic orders.
Providers naturally temper such instructions, exacer-
bating the already problematic adherence issue with a
2-week regimen of dosing.
Most of these fear-related issues could be resolved
with a point-of-care device that is practical and
robust at the periphery of healthcare delivery where
most malaria patients live.19 Figure 3 illustrates the
many problems potentially solved by such a device.
Recent evidence has uncovered yet another poten-
tially serious problem with primaquine — a mutation
to cytochrome P-450 2D6 enzyme seriously impacts
primaquine metabolism and degrades its efficacy
against relapse.20 The frequency of mutant CYP2D6
among relatively extensively studied Caucasian popu-
lations ranged from 3% to 9%.21 If similarly high
frequencies occur among the many diverse ethnic
groups of Asia, those would define the proportion of
patients in whom relapse cannot be prevented using
primaquine.
The Most Vulnerable — Impossible to Treat
Even assuming the availability of a robust point-of-
care diagnostic device, proven safe and efficacious
short dosing regimens of primaquine, and relatively
low frequencies of CYP2D6 mutants (all optimizing
effectiveness of the drug), there still remain very
significant sub-populations that cannot be treated
with primaquine. Unfortunately, these happen to be
the same subpopulations most vulnerable to serious
illness caused by vivax malaria — pregnant and
lactating women, and infants.22–25 Primaquine can-
not be prescribed to pregnant women due to the
unknowable (as a practical rather than technical
matter) G6PD status of the fetus. Most authorities
recommend against primaquine during the first year
of life, and some even exclude children up to the age
of 4 years (WHO, for example26). Absent prolonged
Figure 3 Diagram illustrating relief to ineffective primaquine therapy (among the G6PD normal majority) and its determinants
and consequences contrasted with the benefits delivered by G6PD status ascertainment.
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chemoprophylaxis or intermittent preventive therapy
(untried strategies in this context), these patients will
not receive primaquine and be subjected to repeated
bouts of acute vivax malaria. Studies have demon-
strated pregnant women, their fetuses, the infants
borne to them, and the first year of life as all being
relatively vulnerable to spontaneous abortion, still-
birth, and severe anemia.22–25 The prevention of in-
fection in childbearing women and infants by means
of minimizing exposure to biting anophelines should
be considered a public health urgency in areas of
transmission of vivax malaria.
Preventable Harm
The successful treatment of vivax malaria in endemic
zones requires overcoming a number of serious
obstacles, and yet much depends on being able to do
so. The failure to systematically attack the hypnozoite
reservoir of P. vivax, which is the rule in most of the
endemic world, results in repeated clinical attacks and
serious illness, and further opportunities for transmis-
sion to others. Owing to the chronic neglect of this
infection — largely driven by the erroneous supposi-
tion of its harmlessness — primaquine remains the
only drug with which to combat that threat in the
clinic. The conspicuous inadequacy of that drug, and
the improbability of a rapid solution to it being grossly
ineffective, should mobilize the global health commu-
nity to re-examine measures aimed at minimizing
mosquito–human contact, especially among the most
vulnerable and untreatable (pregnant women and
infants). Relatively aggressive measures are both
indicated and likely achievable. These groups already
represent the highest priority in programs distributing
long-lasting insecticide-treated netting. Expanding
such protection to treated curtains, indoor residual
spraying of insecticides, spatial and topical repellants,
and a variety of other personal protection measures
ought to be strategized and implemented. For the time
being, such represents the sole practical means of
acting to mitigate the harm caused by vivax malaria.
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